Streetbeat News

Stock Prices

EBIX

Ebix reported Q2 earnings of $0.23 per share, missing the analyst consensus estimate of $0.24 by 4.17%. The company's quarterly sales were $118.43 million, missing the analyst consensus estimate of $197.88 million by 40.15%. This represents a 69.33% decrease in earnings and a 52.78% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:45 pm

AVNS

Trading of Avanos Medical shares has been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:43 pm

TTOO

T2 Biosystems, Inc. (NASDAQ:TTOO) has regained compliance with the NASDAQ's market value of listed securities (MVLS) requirement. The company was previously notified of non-compliance due to failure to maintain a MVLS of at least $35 million for 30 consecutive business days. To regain compliance, T2 Biosystems maintained a MVLS of at least $35 million for 10 consecutive trading days. The company must still demonstrate compliance with the Bid Price Rule by November 20, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:39 pm

CB

CVS

JEPQ

MS

On CNBC's 'Halftime Report Final Trades', several financial experts gave their opinions on various stocks and ETFs. Bryn Talkington recommended JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) due to its 10% distribution yield. Josh Brown suggested Chubb Limited (CB) following its better-than-expected Q2 results. Sarat Sethi defended Morgan Stanley (MS) which was beaten down on Tuesday, despite its strong Q2 results. Stephanie Link recommended CVS Health Corporation (CVS) which she considers undervalued and highlighted its Q2 sales increase of 10.3% YoY.

Portfolio Pulse from Lisa Levin

August 09, 2023 | 12:38 pm

WE

BTIG analyst Thomas Catherwood has downgraded WeWork (NYSE:WE) from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 12:36 pm

PUBM

Macquarie analyst Tim Nollen has downgraded PubMatic (NASDAQ:PUBM) from Outperform to Neutral and lowered the price target from $23 to $16.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 12:35 pm

LLY

NVO

Eli Lilly & Co. (LLY) stock surged nearly 15% to a new record high following better-than-expected Q2 earnings and revenue, and raised full-year guidance. The stock also benefited from positive data reported by Novo Nordisk (NVO) for its weight loss drug Wegovy. CNBC's Jim Cramer suggested that LLY could rise further. A Jefferies analyst upgraded LLY to Buy with a $615 price target.

Portfolio Pulse from Shanthi Rexaline

August 09, 2023 | 12:34 pm

CARV

Carver Bancorp has announced that its President and CEO, Michael Pugh, will be leaving the company effective September 30.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 12:34 pm

STGW

Stephens & Co. analyst Nicholas Zangler has downgraded Stagwell (NASDAQ:STGW) from Overweight to Equal-Weight and lowered the price target from $11 to $8.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 12:34 pm

SCPL

Wedbush analyst Michael Pachter has downgraded SciPlay (NASDAQ:SCPL) from Outperform to Neutral and announced a $23 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 12:32 pm